title: The use of hemostatic agents and sealants in urology.
abstract: OBJECTIVE
  While hemostatic agents and sealants have long been used in the fields of surgery and urology, confusion persists about their indications for use and the optimal agent choice. We comprehensively defined and evaluated the scientific basis for hemostatic agent and sealant use in urology, and provide a conceptual framework for future research and discussion.
  
  
  METHODS
  A MEDLINE search of all available literature concerning hemostatic agents in urology was performed, including topical hemostats, anti-fibrinolytics, fibrin sealants and matrix hemostats. Select references were also chosen from the broader surgical literature. Animal studies, case reports, retrospective and prospective studies, and opinion articles were reviewed.
  
  
  RESULTS
  Hemostatic agents include a wide range of components. Recent literature has focused on fibrin sealants and matrix agents. Two main indications exist for hemostatic agents, including 1) hemostasis and 2) sealant. The best evidence for efficacy and safety exists for hemostasis, especially for nephrectomy and trauma. Newer data highlight urinary tract reconstruction, fistula and percutaneous tract closure, suture line strengthening and infertility as potential uses. Novel drug delivery and tissue engineering are areas with large clinical potential.
  
  
  CONCLUSIONS
  Hemostatic agent use is promising and yet unproven for most conditions currently treated in urology. Hemostasis continues to be the main indication, which is well established. Few trials have examined comparative efficacy among hemostatic agents and further prospective studies are needed to justify additional indications as well as determine the optimal mode of use. Minimally invasive surgery will further drive the use of hemostatic agents and sealants. Cost-effective, evidence based hemostatic agent use will continue to challenge all urologists.
authors.affiliation: Division of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Y Mark
authors.initials: YM
authors.lastname: Hong
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Loughlin
mesh_terms: D000714:Anastomosis, Surgical; D000818:Animals; D002483:Cellulose, Oxidized / Q000627:therapeutic use; D015718:Fibrin Tissue Adhesive / Q000627:therapeutic use*; D005781:Gelatin Sponge, Absorbable / Q000627:therapeutic use; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D014014:Tissue Adhesives / Q000627:therapeutic use*; D023822:Tissue Engineering; D013520:Urologic Surgical Procedures
chemical_list: D002483:Cellulose, Oxidized; D015718:Fibrin Tissue Adhesive; C411004:FloSeal Matrix; D006490:Hemostatics; D014014:Tissue Adhesives; C013695:Surgicel